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Substance P – a possible PET diagnostic agent
BACKGROUND
Supstance P (SP) is the most prominent member of tachykinine family and has been known to trigger biological responses by
linking to (mostly) NK 1 receptors. The presence of functional NK1 receptors has already been documented in malignant brain
tumors of glial origin, medullary thyroid cancer, non-small cell lung cancer and pancreatic carcinoma. Also, some studies have
confirmed the presence of Substance P receptors in breast cancer, colon cancer and lymphomas. Development of diagnostic
equivalents to Substance P, may allow easier localization of primary cancers and targeting a therapeutic radioisotopes to these
receptors may be used for the treatment of malignancies that express them, through possible reduction of the blood supply and
tumor draining.
METHODOLOGY
99mTc and 188Re radiolabeled Substance P was tested for
cell surface binding after incubation with NK1 receptor
expressing U-87 MG cells, and negative controll cell line
L-929. The cell culture was incubated for 15 min with the
radiolabeled Substance P and the activity was measured in
gamma counter. The results were performed in triplicate and
were presented as a percentage of initial activity added.
The preliminary whole-body biodistribution studies were
carried out with 99mTc labeled SP using a hybrid SPECT/CT
YAP(S)PET (small-animal tomography scanner).
RESULTS
Our results using 99mTc and 188Re radiolabeled Substance P, demonstrated that the affinity of these radioconjugates for NK1
receptor expressing cells, showed pronounced cell surface binding after incubation with U-87 MG cells, compared to the negative
control cell line L-929 (Table 1). Further preliminary whole-body biodistribution studies with 99mTc labeled SP using a hybrid
SPECT/CT YAP(S)PET small-animal tomography scanner, showed a predominant kidney elimination 60 min post injection,
which is expected for peptides, and an uptake in a region associated with the thymus. Although cardiac uptake was suspected in
this region, it was excluded with ex-vivo measurement of the thymus gland, which after 60 min. showed high, detectable uptake
of 0.0132%IA/g. This finding confirmed the previous findings about the localization of specific SP binding sites.
CONCLUSION
Following the success of 68Ga-DOTATOC, and knowing that
receptor targeted imaging may provide better diagnostic
outcomes in comparison with registering a high glucose
uptake in the affected area using [18F]FDG, we believe that it
would be interesting to consider new radiochemistry
approaches of radiolabeling Substance P with 68Ga. 68Ga (or
other PET radionuclides) may provide better screening and
possible detection of malignant brain tumors of glial origin,
but also other diseases known to express NK1 receptors.
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Fig. 1. Representative coronal sections recorded 20 minutes after 
administration of [99mTc(N)(Cys-Cys-SP)(PCN)] in mouse:
A) salivary glands, B) heart and/or thymus, C) kidney, D) bladder, E) 
liver, F) digestive system, G) X-ray image of the test mice.
Cell line
% of initial added 
activity
[99mTc(N)(Cys-Cys-SP)(PCN)]
% of initial added 
activity
[188Re(N)(Cys-Cys-SP)(PCN)]
U-87 MG 58,49 ± 0,35 61,37 ± 1,02
L-929 2,95 ±1,17 1,96 ± 0,95
Table 1. Cell uptake, expressed as a percentage of the
initial activity added.
